Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,281 | $11.23 Strike: $11.23 | $36,845.63 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · derivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 Underlying: Common Stock · 3,281 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F8 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,281 | $11.23 Strike: $11.23 | $36,845.63 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · derivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,969 Underlying: Common Stock · 3,281 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F8 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,441 | $45.34 | $65,329.18 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.02 to $45.72 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,934 | $44.45 | $130,428.04 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,965 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.98 to $44.92 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,375 | $18.01 | $78,793.75 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,399 | $45.31 | $63,394.29 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.02 to $45.63 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,976 | $44.46 | $132,312.96 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,923 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.99 to $44.92 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,375 | $18.01 | $78,793.75 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,098 | $45.34 | $49,786.61 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.02 to $45.68 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,183 | $44.46 | $97,047.45 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.98 to $44.92 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,281 | $11.23 | $36,845.63 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $45.34 | $45,342.00 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.02 to $45.65 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,281 | $44.48 | $101,456.60 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $43.98 to $44.92 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,281 | $11.23 | $36,845.63 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 17,500 | $18.01 Strike: $18.01 | $315,175.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 33 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 17,500 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F5 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,142 | $11.23 Strike: $11.23 | $24,054.66 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 32 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 2,142 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F4 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 70,849 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 31 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,849 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 7,307 | $27.05 Strike: $27.05 | $197,654.35 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 30 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,849 Underlying: Common Stock · 7,307 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 384 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 29 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 5,910 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 28 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,910 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 17,500 | $45.00 | $787,500.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 22 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 17,500 | $18.01 | $315,175.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 21 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,142 | $45.00 | $96,390.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 20 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,142 | $11.23 | $24,054.66 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 19 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 70,849 | $45.00 | $3,188,205.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 18 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 70,849 | $27.05 | $1,916,465.45 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,307 | $45.00 | $328,815.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,307 | $27.05 | $197,654.35 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 384 | $45.00 | $17,280.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 384 | $10.85 | $4,166.40 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,910 | $45.00 | $265,950.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,910 | $10.85 | $64,123.50 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,140 | $11.23 Strike: $11.23 | $12,802.20 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 27 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,392 Underlying: Common Stock · 1,140 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F4 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 22,968 | $11.23 Strike: $11.23 | $257,930.64 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 26 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 22,968 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F4 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,844 | $27.05 Strike: $27.05 | $49,880.20 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 25 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,156 Underlying: Common Stock · 1,844 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 44,090 | $10.85 Strike: $10.85 | $478,376.50 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 24 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,910 Underlying: Common Stock · 44,090 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 7,533 | $10.85 Strike: $10.85 | $81,733.05 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · derivative · entry 23 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384 Underlying: Common Stock · 7,533 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,140 | $45.00 | $51,300.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,140 | $11.23 | $12,802.20 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 22,968 | $45.00 | $1,033,560.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 22,968 | $11.23 | $257,930.64 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,844 | $45.00 | $82,980.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,844 | $27.05 | $49,880.20 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 44,090 | $45.00 | $1,984,050.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 44,090 | $10.85 | $478,376.50 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,533 | $45.00 | $338,985.00 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 22:46 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,533 | $10.85 | $81,733.05 |
DisclosureSEC source: 0001070081-19-000041 · wf-form4_156210756637582.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F2 · balance_after: Includes 1,112 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2017, 663 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2018 and 715 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2018. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:53 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003207 · a4.xml · derivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:53 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 72,500 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003207 · a4.xml · derivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 70,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000019 · wf-form4_151518657112093.xml · derivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.